Boston Scientific Reports Breakthrough in Heart Disease Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 34 minutes ago
0mins
Should l Buy BSX?
Source: Newsfilter
- Clinical Trial Success: Boston Scientific's FRACTURE trial demonstrated a 93.3% freedom from major adverse cardiac events in 420 patients with severe coronary artery disease, exceeding the expected target of 86.2%, showcasing the safety and efficacy of the SEISMIQ 4CE catheter.
- High Procedural Success Rate: The trial achieved a procedural success rate of 93.7%, with successful stent delivery and a final residual stenosis of less than 50%, not only meeting the primary effectiveness endpoint but also providing new options for complex interventional procedures.
- Innovative Device: The SEISMIQ 4CE catheter employs laser energy to generate acoustic waves that effectively fracture calcium, ensuring optimal stent expansion and improving blood flow, highlighting the device's potential in treating severely calcified lesions.
- Broad Market Potential: As coronary artery disease and IVL therapy continue to grow rapidly, the trial data will enhance understanding of treatment for severely diseased lesions, potentially broadening coronary IVL treatment options and improving patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.680
Low
94.00
Averages
108.14
High
132.00
Current: 52.680
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Invests $1.5 Billion for Stake in MiRus
- Strategic Investment: Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, aiming to enhance its competitive edge in medical technology through the development of new biomaterials and cardiovascular treatment solutions.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system, which is expected to diversify its product portfolio and increase market appeal.
- Clinical Trial Progress: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, demonstrating the technology's potential in treating aortic stenosis and possibly improving patient outcomes.
- Future Earnings Outlook: While the investment is expected to have an immaterial impact on Boston Scientific's adjusted earnings per share in 2026, a successful acquisition of MiRus could generate substantial financial returns through future sales revenue.
See More
Boston Scientific Reports Positive Results from FRACTURE Trial
- High Success Rates: The FRACTURE trial demonstrated that the SEISMIQ™ 4CE catheter achieved low rates of major adverse cardiac events within 30 days, with successful stent delivery in all patients, underscoring the device's safety and effectiveness.
- Patient Recruitment: A total of 420 patients with severe coronary artery disease were enrolled in the trial, with all participants to be followed for two years post-procedure, ensuring the long-term validity and reliability of the data.
- Technological Innovation: The SEISMIQ 4CE catheter employs laser energy to generate acoustic waves that effectively fracture calcium, significantly improving stent implantation success rates and potentially offering new treatment options for complex percutaneous coronary interventions.
- Broad Market Potential: As the prevalence of coronary artery disease rises, the adoption of IVL therapy is rapidly increasing, and the data from the FRACTURE trial will provide crucial support for regulatory submissions of the SEISMIQ 4CE catheter, potentially driving further advancements in this field.
See More
Boston Scientific Reports Breakthrough in Heart Disease Treatment
- Clinical Trial Success: Boston Scientific's FRACTURE trial demonstrated a 93.3% freedom from major adverse cardiac events in 420 patients with severe coronary artery disease, exceeding the expected target of 86.2%, showcasing the safety and efficacy of the SEISMIQ 4CE catheter.
- High Procedural Success Rate: The trial achieved a procedural success rate of 93.7%, with successful stent delivery and a final residual stenosis of less than 50%, not only meeting the primary effectiveness endpoint but also providing new options for complex interventional procedures.
- Innovative Device: The SEISMIQ 4CE catheter employs laser energy to generate acoustic waves that effectively fracture calcium, ensuring optimal stent expansion and improving blood flow, highlighting the device's potential in treating severely calcified lesions.
- Broad Market Potential: As coronary artery disease and IVL therapy continue to grow rapidly, the trial data will enhance understanding of treatment for severely diseased lesions, potentially broadening coronary IVL treatment options and improving patient outcomes.
See More
Mixed US Stock Close as Oil Prices Volatile Amid Geopolitical Tensions
- Mixed Market Performance: The S&P 500 index fell by 0.07%, while the Dow Jones Industrial Average rose by 0.32%, and the Nasdaq 100 index decreased by 0.45%, indicating a divergence in market performance amid oil price volatility and geopolitical tensions.
- Oil Price Volatility: Crude oil prices surged to a three-week high on Monday due to Iran's comments on US demands being 'excessive and unrealistic', but prices fell sharply later when President Trump canceled a planned strike on Iran, highlighting the direct impact of geopolitical events on the market.
- Supportive Economic Data: The May NAHB housing market index rose by 3 to 37, exceeding expectations, which indicates resilience in the housing market and may provide some support for stocks.
- Weak Chinese Economic Indicators: China's April industrial production rose by 4.1% year-on-year, below the expected 6.0%, with retail sales and new home prices also underperforming, reflecting potential risks to global growth prospects.
See More
Boston Scientific Announces $2 Billion Share Buyback Program
- Share Buyback Program: Boston Scientific has entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase, part of a $5 billion buyback initiative, which is expected to add approximately $0.02 to adjusted earnings per share by 2026, thereby boosting investor confidence.
- Strategic Investment in MiRus: The company will invest $1.5 billion to acquire a 34% stake in MiRus, a firm specializing in biomaterials and implant technologies for cardiovascular and orthopedic diseases, with the deal expected to have minimal impact on adjusted earnings per share in 2026 while laying the groundwork for future growth.
- Positive Market Reaction: Shares of Boston Scientific rose 5% following a series of corporate updates, indicating strong investor sentiment towards its strategic investments and buyback plans, despite the stock's nearly 43% decline this year.
- Analyst Rating Adjustment: Bank of America lowered its price target on Boston Scientific from $105 to $68 while maintaining a 'Buy' rating, reflecting concerns over the changing medtech valuation environment, which may impact future stock performance.
See More
NextEra's Acquisition of Dominion Drives Stock Surge
- Acquisition Impact: NextEra Energy's announcement of an all-stock acquisition of Dominion Energy led to a more than 9% surge in Dominion's shares, positioning the combined entity as the world's largest regulated electric utility, significantly enhancing market presence.
- Cruise Industry Recovery: Viking Holdings' stock rose nearly 2% after Wells Fargo upgraded its rating to overweight, with 2027 advanced bookings up 31% from the previous year, indicating strong demand despite concerns over the U.S.-Iran conflict.
- Stock Buyback Plan: Cognizant Technology Solutions saw its shares increase by nearly 7% after doubling its stock repurchase target to approximately $2 billion for this year, which is expected to boost investor confidence and enhance shareholder value.
- Medical Device Investment: Boston Scientific's shares rose over 3% as it announced a $2 billion accelerated stock repurchase plan and a $1.5 billion investment in MiRus, allowing it to re-enter the transcatheter aortic valve replacement market, demonstrating strategic expansion in the medical field.
See More
Boston Scientific Invests $1.5 Billion for Stake in MiRus
- Strategic Investment: Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, aiming to enhance its competitive edge in medical technology through the development of new biomaterials and cardiovascular treatment solutions.
- Exclusive Acquisition Option: The investment agreement includes an exclusive option for Boston Scientific to acquire MiRus's SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement system, which is expected to diversify its product portfolio and increase market appeal.
- Clinical Trial Progress: MiRus has initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve in 1,025 patients, demonstrating the technology's potential in treating aortic stenosis and possibly improving patient outcomes.
- Future Earnings Outlook: While the investment is expected to have an immaterial impact on Boston Scientific's adjusted earnings per share in 2026, a successful acquisition of MiRus could generate substantial financial returns through future sales revenue.
See More
Boston Scientific Reports Positive Results from FRACTURE Trial
- High Success Rates: The FRACTURE trial demonstrated that the SEISMIQ™ 4CE catheter achieved low rates of major adverse cardiac events within 30 days, with successful stent delivery in all patients, underscoring the device's safety and effectiveness.
- Patient Recruitment: A total of 420 patients with severe coronary artery disease were enrolled in the trial, with all participants to be followed for two years post-procedure, ensuring the long-term validity and reliability of the data.
- Technological Innovation: The SEISMIQ 4CE catheter employs laser energy to generate acoustic waves that effectively fracture calcium, significantly improving stent implantation success rates and potentially offering new treatment options for complex percutaneous coronary interventions.
- Broad Market Potential: As the prevalence of coronary artery disease rises, the adoption of IVL therapy is rapidly increasing, and the data from the FRACTURE trial will provide crucial support for regulatory submissions of the SEISMIQ 4CE catheter, potentially driving further advancements in this field.
See More
Boston Scientific Reports Breakthrough in Heart Disease Treatment
- Clinical Trial Success: Boston Scientific's FRACTURE trial demonstrated a 93.3% freedom from major adverse cardiac events in 420 patients with severe coronary artery disease, exceeding the expected target of 86.2%, showcasing the safety and efficacy of the SEISMIQ 4CE catheter.
- High Procedural Success Rate: The trial achieved a procedural success rate of 93.7%, with successful stent delivery and a final residual stenosis of less than 50%, not only meeting the primary effectiveness endpoint but also providing new options for complex interventional procedures.
- Innovative Device: The SEISMIQ 4CE catheter employs laser energy to generate acoustic waves that effectively fracture calcium, ensuring optimal stent expansion and improving blood flow, highlighting the device's potential in treating severely calcified lesions.
- Broad Market Potential: As coronary artery disease and IVL therapy continue to grow rapidly, the trial data will enhance understanding of treatment for severely diseased lesions, potentially broadening coronary IVL treatment options and improving patient outcomes.
See More
Mixed US Stock Close as Oil Prices Volatile Amid Geopolitical Tensions
- Mixed Market Performance: The S&P 500 index fell by 0.07%, while the Dow Jones Industrial Average rose by 0.32%, and the Nasdaq 100 index decreased by 0.45%, indicating a divergence in market performance amid oil price volatility and geopolitical tensions.
- Oil Price Volatility: Crude oil prices surged to a three-week high on Monday due to Iran's comments on US demands being 'excessive and unrealistic', but prices fell sharply later when President Trump canceled a planned strike on Iran, highlighting the direct impact of geopolitical events on the market.
- Supportive Economic Data: The May NAHB housing market index rose by 3 to 37, exceeding expectations, which indicates resilience in the housing market and may provide some support for stocks.
- Weak Chinese Economic Indicators: China's April industrial production rose by 4.1% year-on-year, below the expected 6.0%, with retail sales and new home prices also underperforming, reflecting potential risks to global growth prospects.
See More
Boston Scientific Announces $2 Billion Share Buyback Program
- Share Buyback Program: Boston Scientific has entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase, part of a $5 billion buyback initiative, which is expected to add approximately $0.02 to adjusted earnings per share by 2026, thereby boosting investor confidence.
- Strategic Investment in MiRus: The company will invest $1.5 billion to acquire a 34% stake in MiRus, a firm specializing in biomaterials and implant technologies for cardiovascular and orthopedic diseases, with the deal expected to have minimal impact on adjusted earnings per share in 2026 while laying the groundwork for future growth.
- Positive Market Reaction: Shares of Boston Scientific rose 5% following a series of corporate updates, indicating strong investor sentiment towards its strategic investments and buyback plans, despite the stock's nearly 43% decline this year.
- Analyst Rating Adjustment: Bank of America lowered its price target on Boston Scientific from $105 to $68 while maintaining a 'Buy' rating, reflecting concerns over the changing medtech valuation environment, which may impact future stock performance.
See More
NextEra's Acquisition of Dominion Drives Stock Surge
- Acquisition Impact: NextEra Energy's announcement of an all-stock acquisition of Dominion Energy led to a more than 9% surge in Dominion's shares, positioning the combined entity as the world's largest regulated electric utility, significantly enhancing market presence.
- Cruise Industry Recovery: Viking Holdings' stock rose nearly 2% after Wells Fargo upgraded its rating to overweight, with 2027 advanced bookings up 31% from the previous year, indicating strong demand despite concerns over the U.S.-Iran conflict.
- Stock Buyback Plan: Cognizant Technology Solutions saw its shares increase by nearly 7% after doubling its stock repurchase target to approximately $2 billion for this year, which is expected to boost investor confidence and enhance shareholder value.
- Medical Device Investment: Boston Scientific's shares rose over 3% as it announced a $2 billion accelerated stock repurchase plan and a $1.5 billion investment in MiRus, allowing it to re-enter the transcatheter aortic valve replacement market, demonstrating strategic expansion in the medical field.
See More
